Table 3.

Treatment (quantile) differences in patients with moderate AD dementia at baseline (solanezumab versus placebo, week 80)

		Patients with Moderate AD dementia at baseline (n = 723)
		ADAS-Cog14		ADCS-iADL
		Sola vs PBO treatment difference	P value∗	Sola vs PBO treatment difference	P value∗
	All patients	0.01	.991	0.51	.55
Percentile	20th	0.13	.90	0.63	.49
	30th	0.30	.70	0.74	.40
	40th	0.05	.95	0.73	.46
	60th	0.14†	.91	0.97	.33
	80th	2.3	.21	0.79	.63

^∗P values were based on Wald test.

^†Values in favor of solanezumab treatment.